{"filing":{"accession_number":"0001193125-26-347853","cik":"0001750284","ticker":"OLMA","company_name":"Olema Pharmaceuticals, Inc.","form":"8-K","filing_date":"2026-08-13","report_date":"2026-08-13","primary_document":"olma-20260813.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1750284/000119312526347853/olma-20260813.htm"},"events":[{"id":27467,"run_id":25039,"accession_number":"0001193125-26-347853","anchor_item_number":"5.02","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"Jason O'Byrne was appointed as Chief Financial Officer, principal financial officer, and principal accounting officer of Olema Pharmaceuticals, effective August 11, 2026, approved by the Board on July 28, 2026. The appointment includes compensatory arrangements including a base salary of $545,000, 45% bonus target, $350,000 sign-on bonus, and a 650,000-share option grant. The CEO emphasized O'Byrne's extensive finance and capital markets leadership experience at major biotechnology firms will be essential as the company approaches pivotal clinical data and commercial launch.","company_name":"Olema Pharmaceuticals, Inc.","ticker":"OLMA","filing_date":"2026-08-13","form":"8-K","submitted_at":null,"items":[{"id":29029,"accession_number":"0001193125-26-347853","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of Jason O'Byrne as Chief Financial Officer, principal financial officer, and principal accounting officer, effective August 11, 2026, approved by the Board on July 28, 2026. While the offer letter includes compensatory arrangements (base salary of $545,000, 45% bonus target, $350,000 sign-on bonus, and a 650,000-share option grant), the principal disclosed action is the appointment of a named executive officer to a critical financial leadership role. This is material to investors as CFO appointments directly affect financial oversight and strategy at a clinical-stage biopharmaceutical company approaching pivotal data and potential commercial launch.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-13T11:07:42.668097+00:00","company_name":"","ticker":null,"filing_date":""},{"id":29030,"accession_number":"0001193125-26-347853","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of Jason O'Byrne as Chief Financial Officer of Olema Pharmaceuticals, effective August 13, 2026. The press release emphasizes his extensive experience in finance and capital markets leadership at major biotechnology firms (Vir Biotechnology, Caribou Biosciences, Audentes/Astellas, Genentech/Roche), and the CEO explicitly states his expertise will be \"essential\" as the company approaches pivotal clinical data and commercial launch. This is a material executive appointment of a named officer to a key C-suite role.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-13T11:07:42.668097+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":29029,"accession_number":"0001193125-26-347853","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of Jason O'Byrne as Chief Financial Officer, principal financial officer, and principal accounting officer, effective August 11, 2026, approved by the Board on July 28, 2026. While the offer letter includes compensatory arrangements (base salary of $545,000, 45% bonus target, $350,000 sign-on bonus, and a 650,000-share option grant), the principal disclosed action is the appointment of a named executive officer to a critical financial leadership role. This is material to investors as CFO appointments directly affect financial oversight and strategy at a clinical-stage biopharmaceutical company approaching pivotal data and potential commercial launch.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-13T11:07:42.668097+00:00","company_name":"Olema Pharmaceuticals, Inc.","ticker":"OLMA","filing_date":"2026-08-13"},{"id":29030,"accession_number":"0001193125-26-347853","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of Jason O'Byrne as Chief Financial Officer of Olema Pharmaceuticals, effective August 13, 2026. The press release emphasizes his extensive experience in finance and capital markets leadership at major biotechnology firms (Vir Biotechnology, Caribou Biosciences, Audentes/Astellas, Genentech/Roche), and the CEO explicitly states his expertise will be \"essential\" as the company approaches pivotal clinical data and commercial launch. This is a material executive appointment of a named officer to a key C-suite role.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-13T11:07:42.668097+00:00","company_name":"Olema Pharmaceuticals, Inc.","ticker":"OLMA","filing_date":"2026-08-13"}]}